Skip to main content

Research

New
History

Explore

Search
Cases
Professionals

Resources

Blog
Pricing
Docs

Sign in Create account

Cases

CourtFilingsPetition dateMore filters

Case

Funded debt

Stage

Exit

Next hearing

Last activity

Petition date

Court

Gamida Cell Ltd.

Chapter 15

Case No. 24-10847·Delaware·Petition date Apr 22, 2024

Research this case Track this case Sign in

OverviewHearings

Upcoming (0)

No upcoming hearings match the current filters.

Past (3)

Chapter 15 Recognition Hearing

May 15, 2024 · 11:00 AM ET

Past — no docketed outcome located

Omnibus Hearing

May 15, 2024

Completed

Status Conference

Apr 23, 2024

Completed

Judge: J. Kate Stickles
Industry: Healthcare
Debtors: 1

Gamida Cell Ltd. (Nasdaq: GMDA) is an Israeli biopharmaceutical company headquartered in Kiryat Gat, Israel, developing cell therapies using its proprietary NAM expansion technology. Its lead product, Omisirge® (omidubicel-onlv), received FDA approval in April 2023 for allogeneic hematopoietic stem cell transplantation in blood cancer patients, priced at $300,000 per patient and generating $1.78 million in 2023 revenues. The company employed 143 people as of early 2024, holds 29 issued patents and 83 pending applications, and maintains a U.S. subsidiary with offices in Boston.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error